Back to News
research

The Healthcare Stock Built for Investors Who Prioritize Capital Preservation

newsfeedback@fool.com (Selena Maranjian)
Loading...
4 min read
0 likes
⚡ Quantum Brief
This medical supply giant has raised dividends for over 50 consecutive years, offering a 2.7% yield with steady growth, making it a rare "Dividend King" in healthcare. The company thrives on recurring revenue from essential products like syringes and catheters, shielding it from policy risks facing drugmakers and hospitals under 2026 Medicaid cuts. Trading at a forward P/E of 12—below its five-year average—it provides a margin of safety, reducing downside risk during market volatility while maintaining 46% gross margins. Shareholder-friendly moves include $250 million in 2026 buybacks and authorization for 10 million more shares, signaling confidence in undervaluation and long-term stability. U.S. healthcare spending hit $15,474 per capita in 2024, ensuring sustained demand for BD’s core products amid industry turbulence and regulatory pressures.
AI Audio Summary
0:00 / 0:00
Click to play
kevin-ku-w7ZyuGYNpRQ-unsplash.jpg
Quantum News · Media Library

By Selena Maranjian – Apr 17, 2026 at 4:35PM ESTKey PointsBecton, Dickinson has been increasing its dividend for more than 50 consecutive years. While diversified, much of its revenue comes from recurring sales of medical supplies.Wanting to invest in healthcare is a savvy instinct. It is, after all, a major expense in America. Per the Peterson-KFF Health System Tracker, "On a per capita basis, total health spending, including government, private, out-of-pocket, research, and infrastructure spending, has increased in the last five decades from $353 per year in 1970 to $15,474 per year in 2024." It can still be vexing, though, to figure out which healthcare stocks are likely to serve you best over the coming years. I'd like to suggest one for your consideration: Becton, Dickinson (BDX +2.40%) -- which also goes by the moniker "BD." It should not only grow for you over time, but it also offers a degree of capital preservation, putting your dollars at less risk than some other healthcare concerns might. Image source: Getty Images. Why Becton, Dickinson? I like this stock for multiple reasons. It's not purely focused on an aspect of healthcare that faces challenges. For example, pharmaceutical companies are being pressured to sharply lower their prices by the Trump administration, and while that can be great for patients, it can present a big profit-shrinking headwind for drugmakers. Similarly, care providers such as doctors and hospitals are at risk of seeing their payment systems changed -- and very likely of treating fewer patients, due to Medicaid cuts. Some hospitals may even be forced to close. Becton, Dickinson, though, gets much of its revenue from products such as syringes, blood collection tubes, catheters, infusion systems, and so on -- which will always be needed, providing recurring revenue. It's also a dividend-paying stock, with a solid recent dividend yield of 2.7%. Better still, that payout has been growing, from a quarterly $0.83 in 2021 to $1.05 in 2026, reflecting an average annual growth rate of 5%. Indeed, the company has hiked its payout annually for more than 50 years. The company is also rewarding shareholders by repurchasing stock. It bought back $250 million worth of shares so far in 2026 (as of late January), and has authorized the purchase of 10 million additional shares. Stock buybacks suggest that management sees the stock as undervalued, and they also reflect a company geared toward rewarding shareholders. ExpandNYSE: BDXBecton, DickinsonToday's Change(2.40%) $3.72Current Price$158.54Key Data PointsMarket Cap$44BDay's Range$155.19 - $159.9552wk Range$127.54 - $187.35Volume3.4MAvg Vol2.7MGross Margin46.07%Dividend Yield2.27% Becton, Dickinson's stock is attractively priced at recent levels, with a recent forward-looking price-to-earnings (P/E) ratio of 12, well below the five-year average of 17. That relatively low price means that Becton, Dickinson offers a margin of safety to investors. As it doesn't seem wildly overvalued, it's not likely to pull back sharply during a market downturn. (Remember -- there will always be occasional market downturns.) It has disappointed investors in the recent past, but it has been working on turning itself around. While investors wait, they can collect a solid dividend income stream.Read NextApr 17, 2026 •By Thomas Niel3 Magnificent Dividend Stocks the Sell-Off Has Put on Sale.

Buy Them Now and Hold Forever.Apr 15, 2026 •By Jason HallDividend Kings of 2026Apr 14, 2026 •By Thomas NielWhat Makes a Healthcare Stock Worth Holding Through a Recession?Apr 14, 2026 •By Motley Fool TranscribingBecton Dickinson (BDX) Q4 2024 Earnings TranscriptApr 14, 2026 •By Motley Fool TranscribingBecton Dickinson (BDX) Q2 2025 Earnings TranscriptApr 14, 2026 •By Motley Fool TranscribingBecton Dickinson (BDX) Q3 2025 Earnings TranscriptAbout the AuthorSelena Maranjian is a contributing personal finance and investing expert at The Motley Fool. Selena has produced The Motley Fool’s nationally syndicated newspaper feature since 1997. She is the author of The Motley Fool Money Guide and Investment Clubs: How to Start and Run One the Motley Fool Way, and the co-author of The Motley Fool Investment Guide for Teens and several editions of The Motley Fool Investment Tax Guide. Prior to The Motley Fool, she worked as a high school teacher and public opinion analyst. She holds a master’s degree in teaching from Brown University and a master’s degree in finance from the Wharton School of the University of Pennsylvania.TMFSelenaStocks MentionedBecton, DickinsonNYSE: BDX$158.54(+2.40%)+$3.72*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Read Original

Tags

drug-discovery

Source Information

Source: The Motley Fool

Discussion

0 professional contributions

Sign in to join this professional discussion.

Be the first to add a constructive contribution.